Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value
$15.73−0.48 (-2.96%)
Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –
Aurinia Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Aurinia Pharmaceuticals's total assets was $825.70M at Sep 30, 2026. For fiscal 2025 it was $751.59M, up 36.5% from the year before. The highest annual figure on record is $751.59M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $751.59M | +36.5% |
| FY2024 | Dec 31, 2024 | $550.65M | +0.5% |
| FY2023 | Dec 31, 2023 | $548.06M | +16.4% |
| FY2022 | Dec 31, 2022 | $470.86M | -13.3% |
| FY2021 | Dec 31, 2021 | $543.37M | +17.2% |
| FY2020 | Dec 31, 2020 | $463.66M | +43.0% |
| FY2019 | Dec 31, 2019 | $324.30M | +122.3% |
| FY2018 | Dec 31, 2018 | $145.86M | -23.2% |
| FY2017 | Dec 31, 2017 | $189.85M | +233.1% |
| FY2016 | Dec 31, 2016 | $57.00M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $825.70M | +56.5% |
| Q2 FY2026 | Jun 30, 2026 | $792.26M | +57.6% |
| Q1 FY2026 | Mar 31, 2026 | $724.00M | +43.4% |
| Q4 FY2025 | Dec 31, 2025 | $751.59M | +36.5% |
| Q3 FY2025 | Sep 30, 2025 | $527.53M | -4.0% |
| Q2 FY2025 | Jun 30, 2025 | $502.56M | -4.0% |
| Q1 FY2025 | Mar 31, 2025 | $504.85M | -2.3% |
| Q4 FY2024 | Dec 31, 2024 | $550.65M | +0.5% |
| Q3 FY2024 | Sep 30, 2024 | $549.36M | -1.0% |
| Q2 FY2024 | Jun 30, 2024 | $523.53M | -4.6% |
| Q1 FY2024 | Mar 31, 2024 | $516.63M | +14.4% |
| Q4 FY2023 | Dec 31, 2023 | $548.06M | +16.4% |
| Q3 FY2023 | Sep 30, 2023 | $555.01M | +13.7% |
| Q2 FY2023 | Jun 30, 2023 | $548.90M | +13.8% |
| Q1 FY2023 | Mar 31, 2023 | $451.76M | -10.9% |
| Q4 FY2022 | Dec 31, 2022 | $470.86M | -13.3% |
| Q3 FY2022 | Sep 30, 2022 | $488.29M | +35.6% |
| Q2 FY2022 | Jun 30, 2022 | $482.15M | +24.8% |
| Q1 FY2022 | Mar 31, 2022 | $506.90M | +21.5% |
| Q4 FY2021 | Dec 31, 2021 | $543.37M | +17.2% |
| Q3 FY2021 | Sep 30, 2021 | $360.07M | +11.0% |
| Q2 FY2021 | Jun 30, 2021 | $386.27M | +164.8% |
| Q1 FY2021 | Mar 31, 2021 | $417.08M | +119.7% |
| Q4 FY2020 | Dec 31, 2020 | $463.66M | +713.5% |
| Q4 FY2019 | Dec 31, 2019 | $324.30M | – |
| Q4 FY2018 | Dec 31, 2018 | $145.86M | – |
| Q4 FY2017 | Dec 31, 2017 | $189.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $57.00M | – |
See a number that looks wrong?